HomeCompareIRT vs LLY

IRT vs LLY: Dividend Comparison 2026

IRT yields 4.59% · LLY yields 0.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LLY wins by $1.50M in total portfolio value· pulled ahead in Year 5
10 years
IRT
IRT
● Live price
4.59%
Share price
$14.81
Annual div
$0.68
5Y div CAGR
10.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.3K
Annual income
$1,914.49
Full IRT calculator →
LLY
LLY
● Live price
0.70%
Share price
$886.67
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.54M
Annual income
$1,207,534.19
Full LLY calculator →

Portfolio growth — IRT vs LLY

📍 LLY pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIRTLLY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IRT + LLY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IRT pays
LLY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IRT
Annual income on $10K today (after 15% tax)
$390.28/yr
After 10yr DRIP, annual income (after tax)
$1,627.32/yr
LLY
Annual income on $10K today (after 15% tax)
$59.72/yr
After 10yr DRIP, annual income (after tax)
$1,026,404.06/yr
At 15% tax rate, LLY beats the other by $1,024,776.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IRT + LLY for your $10,000?

IRT: 50%LLY: 50%
100% LLY50/50100% IRT
Portfolio after 10yr
$785.5K
Annual income
$604,724.34/yr
Blended yield
76.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LLY right now

IRT
Analyst Ratings
19
Buy
8
Hold
Consensus: Buy
Price Target
$20.08
+35.6% upside vs current
Range: $18.00 — $22.00
Altman Z
0.7
Piotroski
6/9
LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+40.3% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IRT buys
0
LLY buys
0
No recent congressional trades found for IRT or LLY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIRTLLY
Forward yield4.59%0.70%
Annual dividend / share$0.68$6.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR10.1%100%
Portfolio after 10y$33.3K$1.54M
Annual income after 10y$1,914.49$1,207,534.19
Total dividends collected$10.7K$1.49M
Payment frequencyquarterlyquarterly
SectorREITHealthcare
Analyst consensusBuyBuy
Analyst price target$20.08$1,243.95

Year-by-year: IRT vs LLY ($10,000, DRIP)

YearIRT PortfolioIRT Income/yrLLY PortfolioLLY Income/yrGap
1$11,206$505.52$10,841$140.53+$365.00IRT
2$12,573$582.88$11,884$284.74+$689.00IRT
3$14,126$672.95$13,299$583.47+$827.00IRT
4$15,893$777.98$15,451$1,220.47+$442.00IRT
5← crossover$17,906$900.64$19,183$2,650.30$1.3KLLY
6$20,203$1,044.12$26,676$6,150.32$6.5KLLY
7$22,830$1,212.23$44,530$15,986.45$21.7KLLY
8$25,837$1,409.50$97,527$49,880.25$71.7KLLY
9$29,287$1,641.41$308,551$204,197.51$279.3KLLY
10$33,252$1,914.49$1,537,684$1,207,534.19$1.50MLLY

IRT vs LLY: Complete Analysis 2026

IRTREIT

Independence Realty Trust, Inc. (NYSE: IRT) is a real estate investment trust that owns and operates multifamily apartment properties across non-gateway U.S. markets, including Atlanta, Louisville, Memphis, and Raleigh. IRT's investment strategy is focused on gaining scale within key amenity rich submarkets that offer good school districts, high-quality retail and major employment centers. IRT aims to provide stockholders attractive risk-adjusted returns through diligent portfolio management, strong operational performance, and a consistent return on capital through distributions and capital appreciation.

Full IRT Calculator →

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →
📬

Get this IRT vs LLY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IRT vs SCHDIRT vs JEPIIRT vs OIRT vs KOIRT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.